Professor Ibrahim Aldoss explains that patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene, a genetic marker known as KMT2Ar, who were treated with revumenib saw an overall response rate of 63%, according to results from a phase II trial being reported during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Video: https://medicaldigest.org/scientific-contents/interview:revumenib-found-effective-against-high-risk-kmt2ar-acute-leukemia